pyrazines has been researched along with plerixafor in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alt, C; Anderson, KC; Azab, AK; Azab, F; Burwick, N; Carlson, AL; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Kung, AL; Leleu, X; Lin, CP; Melhem, MR; Moreau, AS; Munshi, NC; Ngo, HT; Ospina, B; Pitsillides, C; Roccaro, AM; Rollins, BJ; Runnels, JM; Sacco, A; Wright, R | 1 |
Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K | 1 |
Chang, CC; Choi, DS; Jiang, B; Su, J; Wen, J; Zhang, L; Zhang, W; Zhou, X | 1 |
Cooper, ML; DiPersio, JF; Eissenberg, L; Ghobadi, A; Holt, MS; Rettig, MP; Ritchey, JK | 1 |
1 trial(s) available for pyrazines and plerixafor
Article | Year |
---|---|
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2011 |
4 other study(ies) available for pyrazines and plerixafor
Article | Year |
---|---|
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Survival; Coculture Techniques; Colony-Forming Units Assay; Cyclams; Drug Resistance, Neoplasm; Fibronectins; Flow Cytometry; Heterocyclic Compounds; Humans; Immunoblotting; Immunoenzyme Techniques; Integrin alpha4beta1; Intercellular Adhesion Molecule-1; Lentivirus; Male; Mice; Mice, SCID; Multiple Myeloma; Pyrazines; Receptors, CXCR4; RNA, Messenger; RNA, Small Interfering; Stromal Cells; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Cohort Studies; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Thalidomide; Time Factors; Transplantation Conditioning; Treatment Outcome | 2013 |
Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.
Topics: Benzylamines; Boronic Acids; Bortezomib; Chemokine CXCL12; Computer Simulation; Cyclams; Drug Delivery Systems; Drug Synergism; Heterocyclic Compounds; Humans; Markov Chains; Models, Biological; Monte Carlo Method; Multiple Myeloma; Neoplastic Stem Cells; Paracrine Communication; Pyrazines; Tumor Microenvironment | 2014 |
Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis.
Topics: Animals; Benzylamines; Boronic Acids; Bortezomib; Cyclams; Drug Synergism; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Integrin alpha4beta1; Mice, Inbred BALB C; Mice, Knockout; Proteasome Inhibitors; Pyrazines; Time Factors; Vascular Cell Adhesion Molecule-1 | 2014 |